1. Home
  2. MLYS vs HBT Comparison

MLYS vs HBT Comparison

Compare MLYS & HBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLYS
  • HBT
  • Stock Information
  • Founded
  • MLYS 2019
  • HBT 1920
  • Country
  • MLYS United States
  • HBT United States
  • Employees
  • MLYS N/A
  • HBT N/A
  • Industry
  • MLYS Biotechnology: Pharmaceutical Preparations
  • HBT Major Banks
  • Sector
  • MLYS Health Care
  • HBT Finance
  • Exchange
  • MLYS Nasdaq
  • HBT Nasdaq
  • Market Cap
  • MLYS 893.0M
  • HBT 746.1M
  • IPO Year
  • MLYS 2023
  • HBT 2019
  • Fundamental
  • Price
  • MLYS $14.66
  • HBT $22.51
  • Analyst Decision
  • MLYS Strong Buy
  • HBT Hold
  • Analyst Count
  • MLYS 3
  • HBT 6
  • Target Price
  • MLYS $27.00
  • HBT $24.17
  • AVG Volume (30 Days)
  • MLYS 2.0M
  • HBT 32.6K
  • Earning Date
  • MLYS 05-08-2025
  • HBT 04-21-2025
  • Dividend Yield
  • MLYS N/A
  • HBT 3.67%
  • EPS Growth
  • MLYS N/A
  • HBT 9.18
  • EPS
  • MLYS N/A
  • HBT 2.26
  • Revenue
  • MLYS N/A
  • HBT $221,390,000.00
  • Revenue This Year
  • MLYS N/A
  • HBT $7.17
  • Revenue Next Year
  • MLYS N/A
  • HBT $1.92
  • P/E Ratio
  • MLYS N/A
  • HBT $10.14
  • Revenue Growth
  • MLYS N/A
  • HBT N/A
  • 52 Week Low
  • MLYS $8.24
  • HBT $18.00
  • 52 Week High
  • MLYS $18.38
  • HBT $26.25
  • Technical
  • Relative Strength Index (RSI)
  • MLYS 56.01
  • HBT 39.10
  • Support Level
  • MLYS $16.15
  • HBT $22.61
  • Resistance Level
  • MLYS $17.21
  • HBT $23.28
  • Average True Range (ATR)
  • MLYS 1.30
  • HBT 0.50
  • MACD
  • MLYS -0.03
  • HBT -0.05
  • Stochastic Oscillator
  • MLYS 36.19
  • HBT 21.64

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

About HBT HBT Financial Inc.

HBT Financial Inc provides a comprehensive suite of business, commercial, wealth management, and retail banking products and services to individuals, businesses, and municipal entities throughout Central and Northeastern Illinois and Eastern Iowa. It operates through one reportable segment: community banking.

Share on Social Networks: